



## argenx to report half year 2020 financial results and second quarter business update on July 30, 2020

July 23, 2020

**Breda, the Netherlands / Ghent, Belgium** – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 30, 2020 at 2:30 pm CET (8:30 am ET) to discuss its second quarter 2020 financial results and provide a business update.

To participate in the conference call, please select your phone number below and use the confirmation code 7470386. The webcast may be accessed on the Investors section of the argenx website at [argenx.com/investors](https://www.argenx.com/investors). A replay of the webcast will be available on the argenx website for 90 days following the call.

### Dial-in numbers:

*Please dial in 5–10 minutes prior to 2:30 p.m. CET/ 8:30 a.m. ET using the number and conference ID below.*

Confirmation Code: **7470386**

Belgium	+32 (0)2 793 3847
Belgium	0800 484 71
France	+33 (0)1 7070 0781
France	0805 101 465
Netherlands	+31 (0)20 0795 6614
Netherlands	0800 023 5015
United Kingdom	+44 (0) 844 481 9752
United Kingdom	0800 279 6619
United States	+1 (646) 741 3167
United States	+1 (877) 870 9135

### About argenx

argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development. argenx is evaluating efgartigimod in multiple serious autoimmune indications and cusatuzumab in hematological malignancies in collaboration with Janssen, along with advancing earlier stage assets within its therapeutic franchises. For more information, visit [www.argenx.com](https://www.argenx.com) and follow us on LinkedIn at <https://www.linkedin.com/company/argenx/>.

### For further information, please contact:

Beth DelGiacco, Vice President Investor Relations (US)  
+1 518 424 4980  
[bdelgiacco@argenx.com](mailto:bdelgiacco@argenx.com)

Joke Comijn, Director Corporate Communications & Investor Relations (EU)  
+32 (0)477 77 29 44  
+32 (0)9 310 34 19  
[info@argenx.com](mailto:info@argenx.com)